



## [www.prostaidcalgary.org](http://www.prostaidcalgary.org)

**“Issue #283” May 2023**

**We Are Back To In Person General Meetings:  
Next Meeting Is Wednesday, May 17 @ 7:30p.m.  
Our New Location Is CKE Community Center 1015 73 Ave SW**

### **May 17th Guest Speaker**

Join us Wednesday, May 17th at 7:30pm where Dr. Tarek Bismar, Professor Departments of Pathology & Laboratory Medicine and Oncology and Department of Biochemistry & Molecular Biology University of Calgary Cumming School of Medicine will join us for a rescheduled meeting to share with us prostate cancer research updates from his studies as a researcher and pathologist at the University of Calgary.



**Dr. Bismar** research achievements include the establishment and directorship of the tissue microarray (TMA) facility at the Lady Davis Institute with the support of Dr. Gerald Batist. This facility was an important step in the support of various investigators research projects pertaining to tissue sectioning, TMA construction and immunohistochemistry. Moreover, Dr. Bismar’s accomplishments also include the establishment of several TMAs for prostate cancer with detailed clinical and pathological outcome, which are currently being utilized in various collaborative projects with several investigators. These collaborations have and continue to be an important part of numerous high impact journal publications and grant submissions. Dr. Bismar’s research accomplishments include the recent characterization of a 10 gene model with prognostic implications in prostate, breast and leukemia, which are currently being validated for potential clinical implementation.

**What's New With Prostaid Calgary**

Our April meeting at our new location, CKE Community Centre, located at 73rd Avenue and Elbow Drive SW, was very well attended with over 20 in-person guests enjoying a very informative message from our guest, Hal Eagletail.

This new location includes a separate place for our Wives, Partners & Caregivers group (Lounge), as well as a separate place for our Warriors group (Boardroom) with a common meeting area for our General meeting presentations.

Meetings are scheduled for the 3rd Wednesday of each month and on Wednesday May 17, we welcome our Wives, Partners & Caregivers, and the Warriors group between 6pm and 7:30pm. The General Meeting presentations will begin starting at 7:30 PM in the Main hall.

We're hoping you can join us as we grow and support one another along our journeys.

If you cannot attend live, we will still be offering the General Meeting via Zoom. Please [RSVP HERE](#) to receive an on-line invite.

Please note that our June meeting will be a Special Celebration of our 30th Anniversary and our Annual General Meeting hosted at the Danish Canadian Club.



## Donate Today

PROSTAID Calgary is a registered charity that relies on the generosity of its members, supporters and friends to achieve its goals. Tax receipts are issued for all amounts over \$20.00.

Your donations are used to support our monthly journal (the Digital Examiner), our free online video library, our website, our outreach programs and general awareness.

[Donate Today](#)

## Connect With Us

Information  
Phone 403 455 1916  
[info@prostaId.org](mailto:info@prostaId.org)  
Brad Sterling  
President  
[president@prostaId.org](mailto:president@prostaId.org)

[Connect With Us](#)

## Support Groups

Frank Altin  
Warriors  
[faltin@telusplanet.net](mailto:faltin@telusplanet.net)  
Wives, Partners & Caregivers  
Newly Diagnosed  
[info@prostaId.org](mailto:info@prostaId.org)

[Meeting Info Here](#)

## Articles Of Interest



## Study Could Guide Therapeutic Choices for mCSPC

Results of a recent systematic review and meta-analysis could help clinicians decide which therapeutic choices to use for the first-line treatment of men with metastatic castration-sensitive prostate cancer (mCSPC).

March 2023

Renal & Urology News

Therapeutic Choices




## CYCLONE 1 Misses Primary End Point But Abemaciclib Shows Activity in mCRPC

Although the phase 2 CYCLONE 1 trial did not meet its primary end point of overall response rate, treatment with abemaciclib did demonstrate clinical activity among patients with metastatic castration-resistant prostate cancer.

April 2023

OneLive

Cyclone 1



## Study shows increase in number of prostate cancer patients choosing active surveillance

Active surveillance includes actively monitoring prostate cancer for progression, with the intention to intervene with surgery or radiation therapy if the cancer progresses.

It is the preferred treatment option for men with low-risk prostate cancer and an option for some men with favorable intermediate-risk prostate cancer.

April 2023

Urology Times

Active Surveillance




## Prostate Cancer Upgrading and Adverse Pathology in Hispanic Men Undergoing Radical Prostatectomy

Outcomes for prostate cancer in Hispanic populations in the United States have been studied less extensively compared with other ethnic groups, despite them being the largest ethnic minority in the United States

March 2023  
URO Today

Hispanic Men



## Hormone Therapy/Radiation Improves PFS in Oligometastatic Prostate Cancer

“This study shows that the combination of metastasis-directed radiation and intermittent hormone therapy significantly improved [PFS], with manageable toxicities, for patients with oligometastatic disease.”

April 2023  
Cancernetwork

Hormone Therapy




## The safety and oncologic benefits of transperineal vs transrectal MRI-guided prostate biopsy

From a targeting standpoint, TP biopsies sample the prostate with an apex-to-base rather than posterior-to-anterior orientation. As such, using a TP approach on lesions that are difficult to reach via TR biopsy, such as anterior and apical lesions, may have better accuracy.

March 2023  
Urology Times

MRI Guided




## OTL78 Shows Safety, Feasibility in PSMA+ Prostate Cancer Detection

The investigational prostate-specific membrane antigen (PSMA)-targeted fluorescent tracer OTL78 was well tolerated among patients with prostate cancer and demonstrated potential to improve detection of prostate cancer, according to findings from a phase 2a study.

April 2023  
Cancernetwork

Prostate Detection



## Enoblituzumab appears safe and efficacious in high-risk prostate cancer

Enoblituzumab appears safe and seems to activate the immune system in a way that involves both T-cells and myeloid cells. What this means is if these results can be replicated in a larger, randomized study, it opens the possibility that combining this therapy with local, curative-intent therapies like surgical prostate removal or radiation therapy would allow this drug to potentially kill micrometastatic disease hiding elsewhere in the body.

April 2023  
Urology Times

Enoblituzumab



## Study highlights efficacy of prostate artery embolization in BPH

This study shows prostate artery embolization to be a safe and highly effective treatment whose long-term outcomes include sustained LUTS relief, significant improvement in quality of life and no change in erectile function,” according to Shivank Bhatia, MD.

March 2023  
Urology Times

BPH




## Combo Shows Promise in High-Risk nmCRPC

Treatment with radiolabeled J591 plus ketoconazole and hydrocortisone may delay time to metastasis in patients with high-risk, non-metastatic castration-resistant prostate cancer (nmCRPC), according to researchers.

March 2023  
Renal & Urology News

Shows Promise



## Once-daily apalutamide tablet available for men with prostate cancer

A once-daily tablet of apalutamide (Erleada) is now available for patients with prostate cancer receiving the androgen receptor inhibitor, according to Janssen Pharmaceutical Companies of Johnson & Johnson.

April 2023  
Urology Times

Once Daily



## Rucaparib for Metastatic Castration-Resistant Prostate Cancer

First-line therapy with rucaparib significantly improves radiographic progression-free survival (rPFS) over physician's choice of therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) harboring BRCA1/2 or ATM alterations.

March 2023  
Oncology Times

Rucaparib

**For Newly Diagnosed**





## 3+4=7 #ProstateCancer | Active Surveillance vs. Focal Therapy |

Patients with Gleason 3+4=7 represent one of the largest "grey areas" in the world of prostate cancer. For patients with Gleason 3+3=6, the medical community knows that active surveillance is the recommended course; for patients with Gleason 4+3=7.

April 2023  
PCRI

[Watch Video Here](#)



## Future Directions in Imaging for Patients With Prostate Cancer

As we look at the problems that we are facing, we have a lot of different tools now and there are even more tools coming to the market. Once we have a lot of tools in our toolbox the question is which tool do we use for the right patient?

[Watch Video Here](#)

P.O. Box 72126  
R.P.O. Glenmore Landing  
Calgary, Alberta T2V 5H9



## For Caregivers & Families



### A physician's advice for defusing patient anger

Here's an all-too-familiar scenario: You walk into the exam room to find your next patient glaring at you, arms crossed, lips pressed together, clearly angry. "It's about time!" the patient seethes. This scenario can also happen at home when you're dealing with a family member, so worth the time to read this if you're a primary caregiver at home or as your job.

April 2023  
Urology Times

[Being A Caregiver](#)

## Articles For Everyone



## Study identifies disparities in prostate cancer screening for transgender women

“Our study has shed light on a major health care disparity for transgender women. The findings reveal that this group is significantly less likely to receive prostate cancer screenings compared [with] cisgender men.”

April 2023  
Urology Times

Transgender



## Mediterranean diet shown superior to Western diet in reducing the risk of prostate cancer

The authors also suggested that the concentration profile of these micronutrients in patients may serve as an indicator to determine those who have a higher risk for prostate cancer. The results from both studies point to adopting a diet with more colorful fruits and vegetables, such as the Mediterranean diet, as opposed to a Western diet or taking supplements.

March 2023  
Urology Times

Mediterranean Diet



## Balancing the benefits and risks of AI in health care

The potential benefits of incorporating AI into health care are numerous but like every technology, AI comes with risks that must be managed if the benefits of these tools are to outweigh the potential costs.

March 2023  
Urology Times

Ai In Health Care





## Impact of an Expanded Definition of Family History on Outcomes of Active Surveillance for Prostate Cancer

An expanded family history suggestive of a hereditary cancer syndrome is an independent predictor of biopsy progression during active surveillance. Men with such a family history may still be offered active surveillance but should be counseled regarding the higher risk of disease progression.

March 2023  
URO Today


[Family History](#)

## New Videos

### Dr. Eric Li and Dr. Rashid Siddiqui discuss nomograms for detecting prostate cancer

“Optimizing detection of clinically significant prostate cancer through nomograms incorporating MRI, clinical features, and advanced serum biomarkers in biopsy naïve men.”

April 2023  
Urology Times



[Watch Video Here](#)

### GI Toxicity Reduction With MRI-Guided SBRT in Prostate Cancer

Dr Kishan discusses the use of MRI-guided SBRT in prostate cancer to reduce acute genitourinary and gastrointestinal toxicity; findings from the MIRAGE study; and how MRI-guided SBRT allows for tighter planning margins, thereby reducing both physician-reported and patient-reported bowel and bladder toxicities.




[Listen To The Podcast Here](#)

## Erectile Dysfunction After Radiation

With the rapid advancements in radiation and imaging technologies since the development of IMRT in the early 2000's, impotence has become one of the last major side effects of men who undergo radiation to cure their prostate cancer.

February 2023  
PCRI



[Watch Video Here](#)

**Volunteers are needed again! We're putting together a volunteer call out list to help out with events as they come up. If you would like to be on that list and you are willing to give 2-3 hours of your time and experience as the needs arise.**

**>>SIGN UP HERE<<**

Thank you to our Sponsors and Community Partners



P.O. Box 72126  
R.P.O. Glenmore Landing  
Calgary, Alberta T2V 5H9



[Unsubscribe](#)